Bone Biologics (NASDAQ:BBLG) Posts Quarterly Earnings Results, Beats Estimates By $6.29 EPS

Bone Biologics (NASDAQ:BBLGGet Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($7.60) by $6.29, reports.

Bone Biologics Trading Down 3.1 %

Bone Biologics stock opened at $2.20 on Friday. The firm has a market capitalization of $1.17 million, a price-to-earnings ratio of -0.04 and a beta of 0.24. The firm has a 50 day simple moving average of $1.95 and a 200 day simple moving average of $3.13. Bone Biologics has a 1-year low of $1.46 and a 1-year high of $55.12.

Bone Biologics Company Profile

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.

Featured Stories

Earnings History for Bone Biologics (NASDAQ:BBLG)

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with's FREE daily email newsletter.